Yesterday, the White House announced a new set of federal actions aimed at lowering the cost of fertility treatments and expanding access to care for families across the country. The guidance recognizes what fertility specialists and patients have long known; IVF is essential healthcare, not elective.
This announcement marks an important milestone for the fertility community and the millions of people who rely on assisted reproductive technologies to build their families.
What the Announcement Includes
The new policies include several initiatives focused on reducing cost barriers and improving accessibility for patients seeking fertility care:
- Lower Fertility Medication Costs
A new pricing agreement with EMD Serono, a leading manufacturer of fertility drugs like Gonal-f and Pergoveris, is expected to reduce the out-of-pocket cost of essential IVF medications.
Beginning in January 2026, these discounted medications will be available through a new federal website, TrumpRx.gov, allowing patients to purchase drugs directly from manufacturers, potentially saving families thousands of dollars per cycle.
- Faster FDA Approvals
The FDA will begin fast-tracking fertility medications, shortening approval times for new or combination drugs like Pergoveris. Faster approval timelines are expected to increase market competition and help bring down costs further.
- Expanded Employer Fertility Benefits
The Departments of Health and Human Services, Labor, and Treasury have released new guidance encouraging employers to offer standalone fertility benefits, like dental or vision coverage. This voluntary option allows employers more flexibility in designing affordable fertility plans, helping employees access care without needing to alter their primary medical insurance.
A Meaningful Step Toward Access and Affordability
Infertility affects nearly 1 in 6 people of reproductive age worldwide, yet financial barriers remain one of the most common obstacles to treatment. In many cases, medications alone account for nearly one-third of total IVF costs, and prices for these drugs have risen more than 80% over the past decade.
These new federal measures represent progress toward making fertility care more attainable, though experts note that implementation and employer participation will determine the true impact. While the new TrumpRx.gov site will help reduce costs for select medications, coverage will depend on individual eligibility and participation by manufacturers.
Our Position: Standing with the Fertility Providers Alliance
Pinnacle Fertility proudly stands with the Fertility Providers Alliance (FPA) in commending the administration’s recognition of IVF as an essential component of reproductive healthcare.
We share the FPA’s call for transparency, equitable access, and patient-centered implementation as these policies take shape.
At Pinnacle, we’ve long championed the integration of fertility care into comprehensive health benefits; promoting cost transparency and employer flexibility that allows more families to access treatment when they need it most.
Looking Ahead
While these steps signal progress, there is still work to be done to ensure fertility care is truly accessible for all. Policymakers, providers, and employers alike have an opportunity to build on this momentum, expanding insurance coverage and continuing to treat fertility as the essential healthcare it is.
At Pinnacle Fertility, we remain steadfast in our mission:
To help families grow through greater access, compassionate care, and advocacy for every path to parenthood. If you’re ready to begin your own fertility journey, our team is here to guide you with expert care and unwavering support — every step of the way.
